Correlation between LDL, HDL, Total Cholesterol, and Triglyceride with the Degree of Chronic Kidney Disease in Children

Ahmedz Widiasta^1, , Sudung O Pardede² and Dedi Rachmadi¹

¹Department of Child Health, Universitas Padjadjaran, Bandung, Indonesia

²Department of Child Health, Universitas Indonesia, Jakarta, Indonesia

Cite this paper

Ahmedz Widiasta, Sudung O Pardede and Dedi Rachmadi. Correlation between LDL, HDL, Total Cholesterol, and Triglyceride with the Degree of Chronic Kidney Disease in Children. American Journal of Clinical Medicine Research. 2017; 5(1):1-5. doi: 10.12691/AJCMR-5-1-1

Abstract

Chronic kidney disease (CKD) is a noncommunicable harmful disease that might decrease child quality of life. The mortality is mostly caused by cardiovascular disease and dyslipidemia as the major risk factor. At present there is lack of study about the correlation between lipid profile and degree of CKD in children. Underlying causes in adults and children are quite different, so it is very important to find out the lipid profile in various degrees of CKD in children. This cross-sectional study was carried out during January–June 2016 in Hasan Sadikin Hospital Bandung and M Djamil General Hospital Padang, Indonesia. Samples were collected consecutively, calculated from coefficient determinant. The power samples gained with G*Power software were 41 children. The study was permitted by the Ethical Committee Hasan Sadikin and M Djamil General Hospital. The correlation was analyzed using multiple linear regression with SPSS 24.0. From the samples we performed ureum, creatinine, LDL, HDL, triglyceride, and total cholesterol. The degree of CKD based on glomerular filtration rate (GFR) was determined by Schwartz formula. The sample consisted of 87 children with CKD stage 1–5 respectively (43, 11, 8, 8, 17). Correlation between GFR with LDL, HDL, triglyceride, and total cholsterol level were: rs=0.29, IK 95% (0.08; 0.49), p=0.007; rs=0.16, IK 95% (-0.07; 0.37), p=0.150; rs=-0.05, IK 95% (-0.26; 0.15), p=0.625; and rs=0.25; IK 95% (0.04; 0.45), p=0.022, respectively. There were significant correlation between various degrees of CKD with LDL and total cholesterol. No significant correlation between various degree of CKD with HDL and triglyceride.

Keywords

chronic kidney disease, HDL, LDL, triglyceride, total cholesterol

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol. 2007; 22: 1999-2009.
[2]	Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006; 290: F262-72.
[3]	Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative. Clinical practie guideline for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: 1-327.
[4]	Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr. Metabolism. 2012, 9:36.
[5]	Massengill SF, Ferris M. Chronic kidney disease in children and adolescent. Pediatr in review. 2014, 35: 16-29.
[6]	Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21: 573-92.
[7]	Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr. Metabolism. 2012, 9: 36.
[8]	Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol. 2010; 25: 711-24.
[9]	Laviano A, Inui A, Marks DL. Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab. 2008; 295: 1000-8.
[10]	Mak RH, Cheung WW, Roberts CT. The growth hormone-insulin-like growth factor-1 axis in chronic kidney disease. Growth Horm IGF Res. 2008; 18: 17-25.
[11]	Bammens B, Evenepoel P, Verberke K, Vanrenterghem Y. Impairment of small intestinal protein assimilation in patients with end stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr. 2004; 80: 1536-43.
[12]	Mooradian AD, Morley JE. Endocrine dysfunction in chronic renal failure. Arch Intern Med. 1984; 144: 351-3.
[13]	Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50:1511-25.
[14]	Musso C, Javor E, Cochran E, Balow JE, Gorden P. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol. 2006; 1:616-22.
[15]	Schaffler A, Muller-Ladner U, Scholmerich J, Buchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006; 27:449-67.
[16]	Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders. Circ Res. 2007; 101:27-39.
[17]	Axelsson J, Qureshi AR, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end stage renal disease. Am J Clin Nutr. 2004; 80:1222-29.
[18]	Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistence, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-92.
[19]	Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care. 2007; 30:239-44.
[20]	Guo Li, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistence in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant. 2009; 24: 1876-83.
[21]	Ayala ER, Pecoits FR, Heimburger O, Lindholm B, Nodfors I, Stenvinkel P. Associations between plasma ghrelin and body composition in end stage renal disease: a longitudinal study. Nephrol Dial Transplant. 2004; 19: 421-6.
[22]	Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39, 175-191.
[23]	Bagdade J, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoprotein in man. J Lab Clin Med. 1976; 87: 38-48.
[24]	Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int. 1981; 19: 625-37.
[25]	Heuck CC, Liersch M, Ritz E, Stegmeier K, Wirth A, Mehls O. Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat. Kidney Int. 2002; 62: 1524-38.
[26]	Majumdar A, Wheeler DC. Lipid abnormalities in renal disease. JR Soc Med. 2000; 93: 178-82.
[27]	Shoji T, Nishizawa Y, Nishitani H, Billheimer JT, Sturley SL. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992; 41: 1653-61.
[28]	Vaziri ND, Liang K, Parks JS. Downregulation of lecithin cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int. 2001; 59: 2192-6.
[29]	Klin M, Smogorzewski M, Ni Z, Zhang G, Mussry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest.1996; 97: 2167-73.
[30]	Liang K, Vaziri ND. Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int. 1999; 56: 621-26.
[31]	Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-1 expression in chronic renal failure. Nephrol Dial Transplant. 1999; 14: 1462-6.
[32]	Liang K, Vaziri ND. Upregulation of acyl-CoA: cholesterol acyl-transferase in chronic renal failure. Am J Physiol Endocrinol Metab. 2002; 283: E676-81.
[33]	Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol. 2004; 287: F1038-43.
[34]	Korczynska J, Stelmanska E, Nogalska A, Szolkiewicz M, Goyke E, Swierczynski J, Rutkowski B. Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1. Metabolism. 2004; 53: 1060-5.
[35]	Rutkowski B, Szolkiewicz M, Korckzynska J, Sucajtys E, Stelmanska E, Nieweglowski T, Swierczynski J. The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis. 2003; 41: S84-8.
[36]	Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, et al. Dyslipidemia in children with chronic kidney disease. Kidney Int 2010; 78(11): 1154-63.